Jasmine Wilson is Director of Clinical Affairs at Neuronoff, Inc.  

Jasmine has led the strategic design and execution of clinical trials for medical device approvals with the US FDA and international regulatory bodies. Her work experience includes early feasibility studies, non-significant risk studies, pilot and pivotal trials ranging from non-invasive to chronically implanted technologies in the field of neuromodulation and drug development. 

Jasmine has over 17 years of experience across several aspects of clinical research, including: Clinical study management: development of protocols, study materials, study execution and closeout, interim analysis reports, clinical study reports, and overseeing CROs and relevant clinical trial vendors; Overall study management and oversight for 22 single and multi-center studies (both domestic and international), which includes: FDA pivotal trials, IDE trials, post-market trials, pilot studies, usability studies, human Factors study, and market research study; Site management: training, monitoring (SQV, SIV, IMV, COV), and performing site audits; Development and maintenance of clinical SOPs, performing internal audits, regulatory audits, and vendor audits. 

Jasmine’s former employers include Abbott, Allergan, Gilead Sciences, Oculeve and Presidio Medical among others, relying on her solid knowledge of FDA regulations, ICH/GCP Guidelines, ISO14155, ISO13485, HIPAA, and the Sunshine Act. Her clinical leadership resulted in studies and approvals for medical devices in the fields of cardiovascular, ophthalmology, bariatric, orthopedic, aesthetics, and chronic pain. Her pharmaceutical clinical trial work was focused on ophthalmology and rare genetic diseases.

Jasmine holds a BS in Health Science & Health Administration from California State University East Bay.